AstraZeneca PLC American Depositary Shares (AZN)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Unveiling Astrazeneca (AZN) Q3 Outlook: Wall Street Estimates for Key Metrics
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Astrazeneca (AZN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2024.
AstraZeneca's China challenges explained
AstraZeneca PLC's (LSE:AZN) stock has suffered in recent days, losing 15% of its value as details emerged about ongoing investigations involving the company's operations in China. Shore Capital analysts have offered further insight into the factors impacting the Anglo-Swedish giant, noting that Chinese authorities are investigating several issues involving the drugmaker's current and former employees.
Buy, Sell, or Hold AstraZeneca Stock? Key Tips Ahead of Q3 Earnings
AstraZeneca's key medicines, mainly cancer drugs, Lynparza, Tagrisso and Imfinzi, and diabetes medicine Farxiga are expected to have driven the company's top line.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC - AZN
NEW YORK, NY / ACCESSWIRE / November 6, 2024 / Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ:AZN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
AstraZeneca: China's investigation into exec separate from medical insurance probe
AstraZeneca said on Wednesday that to its knowledge an ongoing investigation by Chinese authorities into the company's top executive, Leon Wang, is separate from a large health insurance fraud case also involving the company.
AstraZeneca commits to cooperting with China fraud probe after billions wiped from valuation
AstraZeneca PLC (LSE:AZN) has committed to working with Chinese authorities after reports several executives were implicated in a fraud case wiped billions off its valuation on Tuesday. Financial media firm Yicai reported dozens of AstraZeneca China senior executives were involved in the country's largest pharmaceutical insurance fraud case for years.
AstraZeneca Shares Slide As Execs in China Face Fraud Investigation
AstraZeneca (AZN) shares dropped Tuesday after a report that dozens of the company's senior executives in China potentially have been implicated in an insurance fraud case, according to a report from The Guardian citing a financial media firm in the country.
Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say
Just two weeks ago, Upstream Bio, Inc. UPB closed its upsized initial public offering (IPO) of 17.25 million shares at $17 per share, with gross proceeds of approximately $293 million.
AstraZeneca sheds £15 billion of market cap as weight-loss-pill data underwhelms investors
AstraZeneca PLC shed £15 billion in market capitalization on Tuesday, after investors were underwhelmed by early data from a trial of a weight-loss pill.
AstraZeneca shares fall on report of potential China probe fallout
AstraZeneca shares recorded their biggest one-day drop since March 2020 on Tuesday following a report that dozens of senior executives at its China unit could be implicated in the largest insurance fraud case in the country's pharma sector in years.
AstraZeneca sheds £15bn in value as weight loss drug data ‘underwhelming'
AstraZeneca PLC (LSE:AZN) shed £15 billion in value on Tuesday as shares plummeted following the release of early data on its weight loss drug portfolio. Shares fell by 8.6% on Tuesday, taking the pharmaceutical firm's market capitalisation from £171.2 billion to £156.2 billion.
AstraZeneca says experimental obesity pill safe and tolerable in early-stage trial
AstraZeneca said on Monday its experimental weight-loss pill, licensed from China's Eccogene, was safe and tolerable in an early-stage trial, with side effects consistent with the GLP-1 drug class.
